Granted Patent
B2
US 10,196,436 · App. 15/867,637 · Granted Feb 5, 2019
Inhibitors of the fibroblast growth factor receptor
Assignee:
BLUEPRINT MEDICINES CORPORATION
C07K14/71A61K31/4375A61K31/517A61K31/519C07D239/42C07D239/84C07D295/155C07D401/04C07D471/04C07D475/00C07D475/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
Claims (1)
1. A compound which is:
Assignments (4)
RELEASE OF SECURITY INTEREST (REEL/FRAME NUMBER 060616/0923)
Recorded Jul 23, 2025
From: TAO TALENTS, LLC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 072193/0847 →
SECURITY INTEREST
Recorded Jul 8, 2022
From: BLUEPRINT MEDICINES CORPORATION
To: TAO TALENTS, LLC
Reel/Frame 060616/0923 →
ASSIGNEE CHANGE OF ADDRESS
Recorded Jul 6, 2018
From: BLUEPRINT MEDICINES CORPORATION
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 046495/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 10, 2018
From: BIFULCO, NEIL; BROOIJMANS, NATASJA; HODOUS, BRIAN L.; KIM, JOSEPH L.; MIDUTURU, CHANDRASEKHAR V.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 044590/0563 →
Continuity (7)
Provisional Application
61746666
· Dec 28, 2012
Provisional Application
61670379
· Jul 11, 2012
Cited By (5)